Trial Profile

A Randomized, 4-Period, Crossover Study to Investigate the Effects of Tolperisone on Measures of Drowsiness and Cognitive Function Compared to Cyclobenzaprine and Placebo

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 02 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tolperisone (Primary) ; Cyclobenzaprine
Indications Back pain; Muscle hypertonia; Muscle spasticity
Focus Pharmacodynamics
Sponsors Neurana Pharmaceuticals

Most Recent Events

25 Jun 2021 According to a Neurana Pharmaceuticals media release, data from this study is accepted and will be presented at the 23rd Annual American Society of Interventional Pain Physicians Meeting (ASIPP)
25 Jun 2021 Results published in the Neurana Pharmaceuticals Media Release
06 Apr 2021 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com